Suboptimal plasma concentrations with posaconazole suspension as prophylaxis in critically ill COVID-19 patients at risk of Covid-associated pulmonary aspergillosis.
Paola MianRonald J TrofAlbertus BeishuizenJoost B MasselinkAlexander D CornetEsther T SportelPublished in: Journal of clinical pharmacy and therapeutics (2021)
Posaconazole suspension should not be used to prevent CAPA in COVID-19 patients on high-dose steroid therapy.